We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent
News

Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent

Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent
News

Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

"We are pleased to expand our leading IP estate with a license to the Baulcombe patent," said Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer of Alnylam. "Alnylam continues to leverage its patent estate for the advancement of innovative medicines to patients and to enable the entire RNAi therapeutics field, with over 30 license agreements formed to date."

Alnylam's IP estate includes issued, allowed, or granted fundamental patents in many of the world's major pharmaceutical markets that claim the broad structural and functional properties of RNAi therapeutic products.

PBL's Managing Director, Dr Jan Chojecki, stated, "We are very pleased to enter into this agreement with Alnylam. We are excited to have Alnylam as a partner, which has an impressive pipeline of RNAi drug candidates in clinical development. This agreement further endorses the strength of our patent estate in the RNAi field and we look forward to working with other partners through our non-exclusive licensing strategy in agricultural, research, diagnostic and therapeutic commercial applications. This is an excellent example of how UK scientific research contributes inventions that have many beneficial applications across the life sciences. We are pleased to be able to make non-exclusive licences available on reasonable commercial terms to assist our partners in delivering benefits to patients in areas of unmet medical need."

Advertisement